Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.90 |
| ▸ | P4HB | P07237 | 6/20 | 0.90 |
| ▸ | GAA | P10253 | 5/20 | 0.90 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.90 |
| ▸ | POLB | P06746 | 4/20 | 0.90 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | ALPL | P05186 | 2/20 | 0.90 |
| ▸ | ALPI | P09923 | 2/20 | 0.90 |
| ▸ | CA12 | O43570 | 2/20 | 0.90 |
| ▸ | CA2 | P00918 | 2/20 | 0.90 |
| ▸ | CA4 | P22748 | 2/20 | 0.90 |
| ▸ | CA7 | P43166 | 2/20 | 0.90 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.90 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.90 |
| ▸ | KDM1A | O60341 | 1/20 | 0.90 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.90 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.90 |
| ▸ | PKM | P14618 | 1/20 | 0.90 |
| ▸ | MAOA | P21397 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963711 | 1.00 | KDM4E (0.90) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL30637437 | 0.96 | KDM4E (0.91) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL20801877 | 0.95 | KDM4E (0.98) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL29724190 | 0.95 | KDM4E (0.98) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL20801872 | 0.95 | KDM4E (0.98) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL27617329 | 0.95 | KDM4E (0.98) | KDM4EP4HBGAAEPHX2POLB | |
| SCHEMBL20801876 | 0.95 | KDM4E (0.98) | KDM4EP4HBGAAEPHX2POLB | |
| Isoquercetin SCHEMBL22495101 | 0.95 | P4HB (1.00) | KDM4EP4HBGAAEPHX2POLB | |
| Isoquercetin SCHEMBL12566342 | 0.95 | P4HB (1.00) | KDM4EP4HBGAAEPHX2POLB | |
| Isoquercetin SCHEMBL19212904 | 0.95 | P4HB (1.00) | KDM4EP4HBGAAEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655015-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | UNIV COLORADO REGENTS (US) | 2024-02-21 | — | — | EP | claimed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | claimed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | claimed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | claimed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | disclosed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | KDM4E 952/4885P4HB 4851/4885GAA 516/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | KDM4E 893/4885P4HB 4848/4885GAA 545/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KDM4E 3242/4885P4HB 3618/4885GAA 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.